Pritelivir, an investigational antiviral for herpes simplex virus, demonstrated strong efficacy in a phase 3 trial, with 62.7% of immunocompromised patients achieving lesion healing. The ...
In a subgroup analysis of people living with HIV enrolled in PRIOH-1, pritelivir demonstrated superior lesion healing, achieving 61% complete ...
Regeneron-Sanofi’s Dupixent recommended by CHMP for EU approval to treat CSU in young children with ongoing symptoms despite treatment: Tarrytown, New York Wednesday, March 4, 2 ...
Pritelivir, an investigational antiviral drug for herpes simplex virus, demonstrated “superior efficacy” in healing lesions ...
Sanofi and Regeneron’s Dupixent recommended for EU approval to treat chronic spontaneous urticaria in young children with ongoing symptoms ...
Three-phase treatment offers patients with HSV infections an alternative to perpetual antiviral management ROATAN, BAY ...
Chinese assets have outgrown a “bargain basement” label as the upfront value of licensing deals involving them has increased, ...
The total crypto market capitalization has dropped from $4.3 trillion in early October to $2.4 trillion at press time. Bitcoin (BTC), which peaked above $126,000 on Oct. 6, is trading 45% lower at $69 ...
Asahi Kasei has unveiled plans to acquire Aicuris in a deal worth 780 million euros ($920 million), marking the latest in a ...
Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on ...
Approval in adults and children aged 6 years and older supported by Phase 3 trial demonstrating Dupixent significantly reduced nasal signs and symptoms, and systemic corticosteroid use or surgery comp ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results